BR0101456A - Combinações de antagonistas do fator deliberação de corticotropina e secretagogos dohormÈnio de crescimento - Google Patents
Combinações de antagonistas do fator deliberação de corticotropina e secretagogos dohormÈnio de crescimentoInfo
- Publication number
- BR0101456A BR0101456A BR0101456-0A BR0101456A BR0101456A BR 0101456 A BR0101456 A BR 0101456A BR 0101456 A BR0101456 A BR 0101456A BR 0101456 A BR0101456 A BR 0101456A
- Authority
- BR
- Brazil
- Prior art keywords
- growth hormone
- combinations
- deliberating
- corticotropin
- hormone secretagogues
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 239000003324 growth hormone secretagogue Substances 0.000 title 1
- 102000018997 Growth Hormone Human genes 0.000 abstract 3
- 108010051696 Growth Hormone Proteins 0.000 abstract 3
- 239000000122 growth hormone Substances 0.000 abstract 3
- 239000000651 prodrug Substances 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 abstract 2
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 abstract 1
- 208000019622 heart disease Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000003488 releasing hormone Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Patente de Invenção: "COMBINAçõES DE ANTAGONISTAS DOFATOR DE LIBERAçãO DE CORTICOTROPINA ESECRETAGOGOS DO HORMÈNIO DE CRESCIMENTO". Apresente invenção é dirigida para composições farmacêuticascompreendendo um antagonista do fator de liberação decorticotropina e um hormónio de crescimento ou um secretagogodo hormónio de crescimento, pró-drogas destes ou saisfarmaceuticamente aceitáveis dos citados compostos ou dascitadas pró-drogas. A invenção é também dirigida para métodos detratar doenças cardíacas (incluindo a insuficiência cardíacacongestiva) em mamíferos e, particularmente, em seres humanos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19669800P | 2000-04-13 | 2000-04-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0101456A true BR0101456A (pt) | 2001-12-04 |
Family
ID=22726481
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0101456-0A BR0101456A (pt) | 2000-04-13 | 2001-04-11 | Combinações de antagonistas do fator deliberação de corticotropina e secretagogos dohormÈnio de crescimento |
Country Status (5)
Country | Link |
---|---|
US (1) | US20010041673A1 (pt) |
EP (1) | EP1149583A3 (pt) |
BR (1) | BR0101456A (pt) |
CA (1) | CA2344089A1 (pt) |
MX (1) | MXPA01003855A (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1449532A1 (en) * | 1999-08-27 | 2004-08-25 | Pfizer Products Inc. | Compound [2-(4-chloro-2,6-dimethyl-phenoxy)- 3,6-dimethyl-pyridin-4-yl]- (1-ethyl-propyl)- amine and use as CRF antagonist |
US6525067B1 (en) * | 1999-11-23 | 2003-02-25 | Pfizer Inc | Substituted heterocyclic derivatives |
IL145106A0 (en) * | 2000-08-30 | 2002-06-30 | Pfizer Prod Inc | Intermittent administration of a geowth hormone secretagogue |
US6867300B2 (en) * | 2000-11-17 | 2005-03-15 | Bristol-Myers Squibb Company | Methods for the preparation of pyrrolotriazine compounds useful as kinase inhibitors |
DE60225127T2 (de) * | 2001-04-30 | 2009-02-19 | Glaxo Group Ltd., Greenford | Kondensierte pyrimidine als antagonisten des corticotropin releasing factor (crf) |
KR20050109990A (ko) * | 2003-03-14 | 2005-11-22 | 머크 샤프 앤드 돔 리미티드 | 경증 인지 장애의 치료 및 알츠하이머 질환의 예방 또는지연 방법 |
CA2538846A1 (en) * | 2003-09-19 | 2005-03-31 | Pfizer Health Ab | Enhanced method of treatment of growth disorders |
US20070293511A1 (en) * | 2003-12-22 | 2007-12-20 | Sb Pharmco Puerto Rico Inc. And Neurocrine Biosciences, Inc., A Corporation | Crf Receptor Antagonists and Methods |
US7459562B2 (en) * | 2004-04-23 | 2008-12-02 | Bristol-Myers Squibb Company | Monocyclic heterocycles as kinase inhibitors |
TW200538453A (en) * | 2004-04-26 | 2005-12-01 | Bristol Myers Squibb Co | Bicyclic heterocycles as kinase inhibitors |
US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
US7432373B2 (en) * | 2004-06-28 | 2008-10-07 | Bristol-Meyers Squibb Company | Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors |
US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
US7504521B2 (en) | 2004-08-05 | 2009-03-17 | Bristol-Myers Squibb Co. | Methods for the preparation of pyrrolotriazine compounds |
PE20060421A1 (es) | 2004-08-12 | 2006-06-01 | Bristol Myers Squibb Co | Procedimiento para preparar un compuesto de pirrolotriazina anilina como inhibidores de cinasa |
DE102005031575A1 (de) * | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Verwendung von Aktivatoren der löslichen Guanylatzyklase zur Förderung der Wundheilung |
EP1757290A1 (en) * | 2005-08-16 | 2007-02-28 | Zentaris GmbH | Novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors |
EP1934219A1 (en) | 2005-09-16 | 2008-06-25 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
CN101657436A (zh) | 2007-02-09 | 2010-02-24 | 特兰齐姆制药公司 | 大环生长素释放肽受体调节剂及其使用方法 |
TW200942549A (en) | 2007-12-17 | 2009-10-16 | Janssen Pharmaceutica Nv | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 |
WO2010086040A1 (en) * | 2009-01-29 | 2010-08-05 | Biomarin Iga, Ltd. | Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy |
KR101774035B1 (ko) | 2009-10-30 | 2017-09-01 | 얀센 파마슈티카 엔.브이. | 이미다조[1,2―b]피리다진 유도체 및 PDE10 저해제로서의 그의 용도 |
US8329705B2 (en) | 2009-12-30 | 2012-12-11 | Arqule, Inc. | Substituted triazolo-pyrazine compounds |
AR080754A1 (es) | 2010-03-09 | 2012-05-09 | Janssen Pharmaceutica Nv | Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10 |
EP2431035A1 (en) | 2010-09-16 | 2012-03-21 | Æterna Zentaris GmbH | Novel Triazole Derivatives with Improved Receptor Activity and Bioavailability Properties as Ghrelin Antagonists of Growth Hormone Secretagogue Receptors |
CN103619846B (zh) | 2011-06-27 | 2016-08-17 | 詹森药业有限公司 | 1-芳基-4-甲基-[1,2,4]三唑[4,3-a]喹喔啉衍生物 |
CN104411312B (zh) | 2012-06-26 | 2018-03-06 | 詹森药业有限公司 | 包括pde2抑制剂例如1‑芳基‑4‑甲基‑[1,2,4]三唑[4,3‑a]‑喹喔啉化合物和pde10抑制剂的用于在治疗神经病学障碍或代谢障碍中使用的组合 |
ES2607184T3 (es) | 2012-07-09 | 2017-03-29 | Janssen Pharmaceutica, N.V. | Inhibidores de la enzima fosfodiesterasa 10 |
JP2018523665A (ja) | 2015-08-06 | 2018-08-23 | キメリックス インコーポレイテッド | 抗ウイルス剤として有用なピロロピリミジンヌクレオシドおよびその類縁体 |
EP3532051A4 (en) * | 2016-10-26 | 2020-08-12 | The Trustees of Indiana University | SMALL MOLECULE PROTEIN ARGININE METHYLTRANSFERASE 5 (PRMT5) INHIBITORS, AND METHODS OF TREATMENT |
WO2019060692A1 (en) | 2017-09-21 | 2019-03-28 | Chimerix, Inc. | MORPHIC FORMS OF 4-AMINO-7- (3,4-DIHYDROXY-5- (HYDROXYMETHYL) -ETRAHYDROFURAN-2-YL) -2-METHYL-7H-PYRROLO [2,3-D] PYRIMIDINE-5-CARBOXAMIDE AND THEIR USES |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4791099A (en) * | 1984-10-29 | 1988-12-13 | Chaovanee Aroonsakul | Method of treatment for central nervous system diseases such as Alzheimer's's disease |
DK49987A (da) * | 1987-01-30 | 1988-07-31 | Nordisk Gentofte | Fremgangsmaade til behandling af infertilitet og middel til anvendelse ved fremgangsmaaden |
US4816439A (en) * | 1987-03-27 | 1989-03-28 | Nordiske Gentofte A/S | The use of human growth hormone for the treatment of intoxicated individuals |
US5268277A (en) * | 1987-08-07 | 1993-12-07 | Eniricerche S.P.A. | Method for the preparation of human growth hormone |
DK372589D0 (da) * | 1989-07-28 | 1989-07-28 | Novo Nordisk As | Protein |
FR2692893B1 (fr) * | 1992-06-24 | 1994-09-02 | Sanofi Elf | Dérivés alkylamino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
US5378686A (en) * | 1992-09-21 | 1995-01-03 | Research Corporation Technologies, Inc. | Therapeutic treatment of fibromyalgia |
SE9303068D0 (sv) * | 1993-09-21 | 1993-09-21 | Kabi Pharmacia Ab | New use |
FR2714059B1 (fr) * | 1993-12-21 | 1996-03-08 | Sanofi Elf | Dérivés amino ramifiés du thiazole, leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent. |
TW530047B (en) * | 1994-06-08 | 2003-05-01 | Pfizer | Corticotropin releasing factor antagonists |
US6403599B1 (en) * | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
FR2735777B1 (fr) * | 1995-06-21 | 1997-09-12 | Sanofi Sa | Derives de 4-phenylaminothiazole, leur procede de preparation et les compositions pharmaceutiques les contenant |
TW432073B (en) * | 1995-12-28 | 2001-05-01 | Pfizer | Pyrazolopyridine compounds |
WO1997034604A1 (en) * | 1996-03-21 | 1997-09-25 | Merck & Co., Inc. | 4-spiroindoline piperidines promote release of growth hormone |
DE69736711T2 (de) * | 1996-08-28 | 2007-09-20 | Pfizer Inc. | Substituierte 6,5-heterobicyclische-derivate |
UA59384C2 (uk) * | 1996-12-20 | 2003-09-15 | Пфайзер, Інк. | Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі |
ES2203937T3 (es) * | 1997-03-26 | 2004-04-16 | Taisho Pharmaceutical Co., Ltd | Derivados de 4-tetrahidropiridilpirimidina. |
TW453999B (en) * | 1997-06-27 | 2001-09-11 | Fujisawa Pharmaceutical Co | Benzimidazole derivatives |
EP1040831A3 (en) * | 1999-04-02 | 2003-05-02 | Pfizer Products Inc. | Use of corticotropin releasing factor (CRF) antagonists to prevent sudden death |
US6387894B1 (en) * | 1999-06-11 | 2002-05-14 | Pfizer Inc. | Use of CRF antagonists and renin-angiotensin system inhibitors |
US6432989B1 (en) * | 1999-08-27 | 2002-08-13 | Pfizer Inc | Use of CRF antagonists to treat circadian rhythm disorders |
IL139197A0 (en) * | 1999-10-29 | 2001-11-25 | Pfizer Prod Inc | Use of corticotropin releasing factor antagonists and related compositions |
EP1159964B1 (en) * | 2000-05-31 | 2009-10-28 | Pfizer Products Inc. | Use of growth hormone secretagogues for stimulating gastrointestinal motility |
-
2001
- 2001-03-30 EP EP01303033A patent/EP1149583A3/en not_active Withdrawn
- 2001-04-11 BR BR0101456-0A patent/BR0101456A/pt not_active IP Right Cessation
- 2001-04-11 MX MXPA01003855A patent/MXPA01003855A/es unknown
- 2001-04-12 CA CA002344089A patent/CA2344089A1/en not_active Abandoned
- 2001-04-13 US US09/834,477 patent/US20010041673A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2344089A1 (en) | 2001-10-13 |
US20010041673A1 (en) | 2001-11-15 |
EP1149583A2 (en) | 2001-10-31 |
MXPA01003855A (es) | 2002-06-04 |
EP1149583A3 (en) | 2001-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0101456A (pt) | Combinações de antagonistas do fator deliberação de corticotropina e secretagogos dohormÈnio de crescimento | |
BR0015908A (pt) | Emprego de compostos org nicos no tratamento de doenças | |
YU92501A (sh) | Levodop/karbidop/entakapon farmaceutski preparat | |
DK1623703T3 (da) | Hydrocodonformuleringer med kontrolleret frigivelse | |
BR0114799A (pt) | Compostos de ácido cianofenoxi carboxìlico e composições para liberar agentes ativos | |
PT1119543E (pt) | N-aralquilaminotetralinas como ligandos para o receptor y5 do neuropeptido y | |
EP1426375A3 (en) | Analgesic spiroindole derivatives | |
BR0011894A (pt) | Forma de dosagem oral, processo para a fabricação de forma de dosagem, uso de forma de dosagem farmacêutica oral, e, métodos para aumentar inibição de secreção do ácido gástrico e para aumentar o efeito terapêutico no tratamento de distúrbios gastrointestinais associados com excesso de secreção ácida | |
ATE375341T1 (de) | Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen | |
RS50876B (sr) | Upotreba flibanserina u lečenju seksualnih poremećaja | |
BR0013478A (pt) | Combinação sinergìstica | |
NZ522326A (en) | Adenosine A2A receptor antagonists | |
CY1107853T1 (el) | Χρησεις αντισπασμωδικων αμινοξεων για τη θεραπευτικη αγωγη διπολικων διαταραχων | |
BR0315777A (pt) | Uso de derivados de piperazina como antagonistas ccr1 | |
BR0012175A (pt) | Antagonistas de receptor de igiur5, seletivos para o tratamento de enxaqueca | |
PT1336407E (pt) | Composicao contendo um antagonista do receptor de angiotensina e um diuretico e sua utilizacao para o tratamento da hipertensao | |
IS8096A (is) | Notkun karbamasepínafleiða til að meðhöndla órósemi í sjúklingum er þjást af vitglöpum | |
IL168704A (en) | Calcilytic compounds, pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising them and their use in the preparation of medicaments for treating disease or disorder characterized by abnormal bone or mineral homeostasis | |
BR0007686A (pt) | Uso de antagonistas receptores da angiotensina ii para tratar enfartação miocárdia aguda | |
BR0000486A (pt) | Antagonistas do neuropeptìdeo y | |
HUP9904173A2 (hu) | Gyógyszerkészítmény vírusos betegségek kezelésére | |
SE9902937D0 (sv) | Pharmaceutical compositions | |
BR0017367A (pt) | Uso de melagatran ou de um seu derivado farmaceuticamente aceitável, método de tratamento de um distúrbio isquêmico em um paciente tendo, ou sob risco de ter, fibrilação atrial não-valvular, e, formulação farmacêutica | |
DE69831416T2 (de) | Chinolin-harnstoff-derivate zur behandlung von entzugssyndrom und durch entzugssyndrom verursachten gehirnschaden | |
DE602006016168D1 (de) | 1,3,5-triazepin-dionen zur Behandlung von Malaria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 1963 DE 19.08.2008. |